静脉血栓栓塞症患者活化蛋白C抗性及凝血因子Ⅴ活性和基因多态性研究.docVIP

静脉血栓栓塞症患者活化蛋白C抗性及凝血因子Ⅴ活性和基因多态性研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：静脉血栓栓塞症患者活化蛋白C抗性及凝血因子Ⅴ活性和基因多态性研究 1 文2：活化蛋白C抗急性肺损伤的研究进展 9 1 ALI发生的相关机制 10 2 APC的产生与活化 11 3 APC的生物学活性与相关机制 11 4 APC的抗ALI作用 14 5 总结 与展望 15 参考文摘引言： 16 原创性声明（模板） 17 文章致谢（模板） 17 正文 静脉血栓栓塞症患者活化蛋白C抗性及凝血因子Ⅴ活性和基因多态性研究 文1：静脉血栓栓塞症患者活化蛋白C抗性及凝血因子Ⅴ活性和基因多态性研究 Analysis of Activated Protein C Resistance, Factor V Coagulation Activity and Gene Polymorphisms in Patients with Venous Thromboembolism Abstract The study was aimed to investigate the factor V coagulation activity (FⅤ:C), and to evaluate FⅤgene polymorphisms and activated protein C resistance (APCR) in the patients with venous thromboembolism (VTE). 95 patients with VTE and 95 normal controls were investigated for FⅤ gene polymorphisms. FV Leiden, FⅤCambridge, and FⅤHong Kong were detected by PCR, MnlI and BstNI digestion respectively. FⅤAsp79His and FⅤI359T were detected by MassARRAYTM. FⅤ:C and APCR in 65 patients with VTE and 60 normal controls were determined by a onestage clotting method and the APTTbased assays respectively. The results showed that the mean levels of plasma FⅤ:C were significantly higher in VTE group than that in controls (%±% vs %±%) (P=), the incidence of APCR were % (13 of 65 cases) in patients with VTE and % (3 of 60 cases) in normal controls (P=）. FV Leiden, FⅤCambridge, FⅤHong Kong, FⅤAsp79His and FⅤI359T mutatio were not found in two groups. It is concluded that the increased plasma level of FⅤ:C is a risk factor for VTE. There is APCR in both groups, APCR is also a risk factor to VTE. APCR may not be associated with mutatio of FV Leiden, FⅤCambridge, FⅤHong Kong, FVAsp79His and FV I359T polymorphisms, other facto need to study further in APCR. Key words venous thromboembolism; activated protein C resistance; factor V coagulation activity; gene polymorphisms J Exp Hematol 2007; 15(3):612-616 静脉血栓栓塞症（venous thromboembolism， VTE）包括深静脉血栓形成 （deep venous thrombosis， DVT）和肺血栓栓塞症（pulmonary thromboe